Sensitivity–Specificity of Tau and Amyloid β Positron Emission Tomography in Frontotemporal Lobar Degeneration

To examine associations between tau and amyloid β (Aβ) molecular positron emission tomography (PET) and both Alzheimer‐related pathology and 4‐repeat tau pathology in autopsy‐confirmed frontotemporal lobar degeneration (FTLD).

[1]  V. Lowe,et al.  In Vivo Imaging and Autoradiography in a Case of Autopsy-Confirmed Pick Disease. , 2019, Neurology. Clinical practice.

[2]  John L. Robinson,et al.  Primary Tau Pathology, Not Copathology, Correlates With Clinical Symptoms in PSP and CBD. , 2019, Journal of neuropathology and experimental neurology.

[3]  Barbara Borroni,et al.  Faculty Opinions recommendation of 18F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes. , 2019 .

[4]  David T. Jones,et al.  Tau-positron emission tomography correlates with neuropathology findings , 2019, Alzheimer's & Dementia.

[5]  David T. Jones,et al.  The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes , 2019, Brain : a journal of neurology.

[6]  David T. Jones,et al.  Neuroimaging correlates with neuropathologic schemes in neurodegenerative disease , 2019, Alzheimer's & Dementia.

[7]  K. Ishii,et al.  Characterization of the binding of tau imaging ligands to melanin-containing cells: putative off-target-binding site , 2019, Annals of Nuclear Medicine.

[8]  Peter R. Martin,et al.  The influence of β-amyloid on [18F]AV-1451 in semantic variant of primary progressive aphasia , 2019, Neurology.

[9]  Maria Luisa Gorno-Tempini,et al.  18F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes , 2019, Alzheimer's Research & Therapy.

[10]  C. Jack,et al.  Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology , 2018, Alzheimer's & Dementia.

[11]  Peter R. Martin,et al.  [18F]AV‐1451 tau‐PET and primary progressive aphasia , 2018, Annals of neurology.

[12]  Peter R. Martin,et al.  [18F] AV-1451 uptake in corticobasal syndrome: the influence of beta-amyloid and clinical presentation , 2018, Journal of Neurology.

[13]  Rene L. Utianski,et al.  Tau-PET imaging with [18F]AV-1451 in primary progressive apraxia of speech , 2018, Cortex.

[14]  Siobhan Ewert,et al.  Toward defining deep brain stimulation targets in MNI space: A subcortical atlas based on multimodal MRI, histology and structural connectivity , 2016, NeuroImage.

[15]  C. Jack,et al.  Pittsburgh Compound B and AV-1451 positron emission tomography assessment of molecular pathologies of Alzheimer's disease in progressive supranuclear palsy. , 2018, Parkinsonism & related disorders.

[16]  Jesse A. Brown,et al.  Clinicopathological correlations in behavioural variant frontotemporal dementia , 2017, Brain : a journal of neurology.

[17]  Luca Passamonti,et al.  [18F]AV-1451 binding in vivo mirrors the expected distribution of TDP-43 pathology in the semantic variant of primary progressive aphasia , 2017, Journal of Neurology, Neurosurgery, and Psychiatry.

[18]  Hanna Cho,et al.  18F-AV-1451 binds to motor-related subcortical gray and white matter in corticobasal syndrome , 2017, Neurology.

[19]  Victor L. Villemagne,et al.  Assessment of amyloid β in pathologically confirmed frontotemporal dementia syndromes , 2017, Alzheimer's & dementia.

[20]  David T. Jones,et al.  Defining imaging biomarker cut points for brain aging and Alzheimer's disease , 2017, Alzheimer's & Dementia.

[21]  Luca Passamonti,et al.  18F-AV-1451 positron emission tomography in Alzheimer’s disease and progressive supranuclear palsy , 2017, Brain : a journal of neurology.

[22]  Hanna Cho,et al.  Subcortical 18F‐AV‐1451 binding patterns in progressive supranuclear palsy , 2017, Movement disorders : official journal of the Movement Disorder Society.

[23]  Anthony J. Spychalla,et al.  [18F]AV‐1451 tau positron emission tomography in progressive supranuclear palsy , 2017, Movement disorders : official journal of the Movement Disorder Society.

[24]  Sang Won Seo,et al.  Regional correlations between [11C]PIB PET and post-mortem burden of amyloid-beta pathology in a diverse neuropathological cohort , 2016, NeuroImage: Clinical.

[25]  M. Schain,et al.  Increased basal ganglia binding of 18 F‐AV‐1451 in patients with progressive supranuclear palsy , 2016, Movement disorders : official journal of the Movement Disorder Society.

[26]  Young T. Hong,et al.  18 FAV-1451 positron emission tomography in Alzheimer ’ s disease and progressive supranuclear palsy , 2017 .

[27]  J. Trojanowski,et al.  Multimodal evaluation demonstrates in vivo 18F-AV-1451 uptake in autopsy-confirmed corticobasal degeneration , 2016, Acta Neuropathologica.

[28]  Nick C Fox,et al.  Characterization of tau positron emission tomography tracer [18F]AV-1451 binding to postmortem tissue in Alzheimer's disease, primary tauopathies, and other dementias , 2016, Alzheimer's & Dementia.

[29]  C. Jack,et al.  [18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration , 2016, Acta Neuropathologica.

[30]  Clifford R. Jack,et al.  An autoradiographic evaluation of AV-1451 Tau PET in dementia , 2016, Acta Neuropathologica Communications.

[31]  Keith A. Johnson,et al.  Validating novel tau positron emission tomography tracer [F‐18]‐AV‐1451 (T807) on postmortem brain tissue , 2015, Annals of neurology.

[32]  Clifford R. Jack,et al.  Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer’s disease spectrum , 2015, Brain : a journal of neurology.

[33]  Janna H. Neltner,et al.  Primary age-related tauopathy (PART): a common pathology associated with human aging , 2014, Acta Neuropathologica.

[34]  H. Shill,et al.  Concomitant pathologies among a spectrum of parkinsonian disorders. , 2014, Parkinsonism & related disorders.

[35]  H. Kolb,et al.  [18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease , 2013, Alzheimer's & Dementia.

[36]  L. Ferrucci,et al.  Correspondence between in vivo 11C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques , 2012, Acta Neuropathologica.

[37]  J. Schneider,et al.  National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease , 2012, Alzheimer's & Dementia.

[38]  Dennis W. Dickson,et al.  Neuropathology of Frontotemporal Lobar Degeneration-Tau (FTLD-Tau) , 2011, Journal of Molecular Neuroscience.

[39]  J. Trojanowski,et al.  A harmonized classification system for FTLD-TDP pathology , 2011, Acta Neuropathologica.

[40]  Charles Duyckaerts,et al.  National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach , 2011, Acta Neuropathologica.

[41]  B. Boeve,et al.  Does TDP-43 type confer a distinct pattern of atrophy in frontotemporal lobar degeneration? , 2010, Neurology.

[42]  D. Dickson,et al.  Cortical Alzheimer type pathology does not influence tau pathology in progressive supranuclear palsy. , 2009, International journal of clinical and experimental pathology.

[43]  Nancy Johnson,et al.  Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia , 2008, Annals of neurology.

[44]  Karl J. Friston,et al.  Unified segmentation , 2005, NeuroImage.

[45]  D. Dickson,et al.  Apolipoprotein E epsilon 4 is a determinant for Alzheimer-type pathologic features in tauopathies, synucleinopathies, and frontotemporal degeneration. , 2004, Archives of neurology.

[46]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[47]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[48]  P. Lantos,et al.  Office of Rare Diseases Neuropathologic Criteria for Corticobasal Degeneration , 2002, Journal of neuropathology and experimental neurology.

[49]  H. Braak,et al.  Phases of Aβ-deposition in the human brain and its relevance for the development of AD , 2002, Neurology.

[50]  D. Dickson.  Neuropathology of Pick’s disease , 2001, Neurology.

[51]  S. M. Sumi,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.

[52]  Z. Khachaturian.  Diagnosis of Alzheimer's disease. , 1985, Archives of neurology.

[53]  Young T. Hong,et al.  AV-1451 binding in vivo mirrors the expected distribution of TDP-43 pathology in the semantic variant of primary progressive aphasia , 2022 .